Several studies have demonstrated the effectiveness of mAbs specific for tumor cell surface molecules as therapeutic agents to inhibit tumor growth both experimentally (1-4) and in clinical trials (5-7). Since B cell lymphomas bear unique determinants (idiotopes) on their surface Ig molecules, and since only a small number of normal B cells share that same idiotype, antiidiotype mAb could be used as an antitumor agent without affecting a significant fraction of the normal B cell population (8, 9). There are, however, two problems with this approach: (a) the high rate ofsomatic mutation in Ig genes (10, 11), which can alter the epitope to be recognized by mAb; and (b) the necessity to establish a different antiidiotypic mAb for each individual B cell lymphoma.
Several studies have demonstrated the effectiveness of mAbs specific for tumor cell surface molecules as therapeutic agents to inhibit tumor growth both experimentally (1) (2) (3) (4) and in clinical trials (5) (6) (7) . Since B cell lymphomas bear unique determinants (idiotopes) on their surface Ig molecules, and since only a small number of normal B cells share that same idiotype, antiidiotype mAb could be used as an antitumor agent without affecting a significant fraction of the normal B cell population (8, 9) . There are, however, two problems with this approach: (a) the high rate ofsomatic mutation in Ig genes (10, 11) , which can alter the epitope to be recognized by mAb; and (b) the necessity to establish a different antiidiotypic mAb for each individual B cell lymphoma.
For T cell tumors, the situation appears to be different. Recent analysis of TCR V gene segments has revealed very limited, ifany, somatic mutation among the TCR genes isolated from various T cell clones, hybridomas, and T cell tumor lines (12) . Furthermore, the number of different TCR V gene segments is relatively small both in man and mouse (13) , and the evidence indicates that deletion of several V gene segments in certain strains ofmice does not affect the general immune status ofsuch mouse strains (14) . These observations raise the intriguing possibility that mAbs directed to determinant of TCR V framework regions, rather than to unique idiotopes of the TCR, might be useful for treating T cell tumors without compromising host immunity. Moreover, because of the small number of TCR V genes, it seems feasible to produce a panel ofmAbs specific for each ofthese V gene products. These mAbs may be effective in diagnosis or clinical protocols dealing with spontaneously arising T cell tumors expressing one of the V gene products .
Here we explore the feasibility ofthis approach in mice and show that mAbs specific for V06 TCR products given four times over a 2-wk period prevent the growth of a V06+ syngeneic T cell tumor without compromising the immune status of these mice to other experimental antigens . To our knowledge, this is the first demonstration of the effectiveness of preventing tumor growth with a mAb having specificity for a particular subset of T cells expressing a defined V(3 TCR marker.
Materials and Methods
Mice. C57BL/6 and B10.BR mice (purchased from TheJackson Laboratories, Bar Harbor, ME) of both sexes, 6-10 wk old, were used.
Cell Lines and mAbs . Two thymoma cell lines, C6VL and EL-4, derived from C57BL/6, and one AKR derived thymoma, BW5147, were maintained in culture in 10% FCS DME . mAb directed to determinant on the TCR V08 chain (KJ16-133, rat IgG2a) (15) and on the Vf6 chain (RR4-7, rat IgG2b) (16) were partially purified from ascites fluids.
Immunofluorescent Staining Two-step surface immunofluorescence staining was performed as described previously (16) . Briefly, tumor cells or nylon wool nonadherent spleen cells were incubated with saturating doses of mAb (100 pl) for 30 min at 4°C, washed, and further incubated with FITC-conjugated goat anti-rat Ig (Caltag Laboratories, San Francisco, CA) for another 30 min at 4°C. Stained samples were analyzed on a FACScan flow cytometer (Becton Dickinson Immunocytometory Systems, Mountain View, CA) .
T Cell Proliferation Assays . Proliferative responses of T cells to antigen and mitogen (Con A) were measured by procedures described previously (17) . Briefly, mice were immunized with keyhole limpet hemocyanin (KLH, 100 Fig/mouse ) in CFA at the base of the tail . 7 d later, 105 cells, recovered from inguinal lymph nodes, were stimulated with KLH (10,ug/ml), Con A (2 1~g/ml), or medium alone in flat-bottomed microtiter plates in a final volume of 200 pl of 5% FCS DME . The proliferative response was measured on day 3 following a 6-h pulse with [3 H]thymidine .
Generation ofAlloantigen-speck CTL. Cytolytic T cell responses were measured by culturing 5 x 106 C57BL/6 spleen cells and an equal number of irradiated (2,000 rad) B10 .BR spleen cells in 24-well tissue culture plates in a final volume of 2 ml 5o7o FCS DME . 5 d later, cells were recovered and tested for cytolytic activity using 5 ICr-labeled BW5147 (H-2') target cells in standard Cr-release assays. Lytic units (LU) were calculated from plots of titrated cytolytic activities. 1 LU is defined as the number of effector cells required to lyse 50 17o of 104 target cells under the specific conditions of this assay system .
Results

Treatment of T Cell Tumor
In Vioo. To test the possible therapeutic efficacy of mAbs specific for V136 on T cell tumor growth in vivo, a large panel of T cell tumors derived from C57BL/6 mice were screened for the expression of V#6 or VQ8 TCR using a mAb specific for V06 (RR4-7) and another specific for V08 (KJ-16 .133) . These two antibodies stain 8 and 13%, respectively, of nylon wool nonadherent B6 spleen cells. One tumor, C6VL, was identified with anti VS6 mAb staining and usage of this TCR gene was confirmed in mRNA analyses using a V06 probe. The results of the first two efficacy tests of antiV06 mAb on the growth of a Va6+ tumor are shown in Table I . Panels of C57BL/6 mice were injected intravenously with lethal numbers (20 x 104) C6VL (V06+) or EL4 (V06-) tumor cells and then treated with anti14(36 mAb, anti 14/38 mAb, or nothing (150 jig/injection, i.p., four times in 12 d). All mice given EL4 tumor cells died, regardless of which antibody they received in subsequent treatment. By comparison, however, of mice injected with VQ6+ tumor cells, only 3/10 animals died after treatment with anti14/36 mAb, while all died (15/15) if treated with anti V08 mAb or nothing. Furthermore, use ofisotype-matched control IgG2b antibody did not protect mice from tumor-related death. It should be noted that of the three mice that died with 14/36 + tumor cells and anti V06 treatment, these had significantly prolonged survival times (>60 d) compared with the other treatment groups (-30 d).
C6VL tumor cells were recovered from a liver mass in a mouse that developed a tumor despite treatment with anti 14(36 mAb. These cells were analyzed for surface expression of V06 TCR by flow cytometric analysis using RR4-7 (antiV06). The data shown in Fig. 2 revealed that this tumor retained the original V06 TCR on a majority of its cells, indicating that treatment of this 1406+ tumor with anti V06 mAb does not result in the selection of significant number ofTCR negative variants in vivo.
Effect ofAnti-V,B6 mAb on Host Immune Responses. Flow cytometric analysis of nylon wool nonadherent spleen cells from mice treated with anti V06 mAb, using anti-V06 and anti 14(38 mAbs, indicated that the number of 1406+ T cells was greatly reduced while number of 14/38+ T cells was normal in both treated and nontreated V06 TCR expression on C6VL tumor cells recovered from mice treated with RR4-7 antibody. Tumor cells from liver in a mouse that developed a tumor despite treatment with RR4-7 Ab were cultured in vitro for 3 d . Cells were stained with medium alone (A) or RR4-7Ab (B) followed by fluoresceinated goat anti-rat Ig. Stained samples were analyzed by FACScan flow cytometry. groups (Table II ). These data demonstrate that anti V06 mAb can eliminate Va6+ tumor cells as well as normal T cells that are V06+ , which comprise -8% of the peripheral T cell pool .
Despite elimination of T cells bearing V06 TCR, this treatment seemed not to have significant effect on the immune status of these mice . T cell responses of mAb treated animals, measured by proliferative response to KLH and Con A, and the generation of allospecific CTL, were comparable to those of nontreated animals (Table  II) .
Immunity to the Tumor Cells after n Ab Treatment. Mice that had been successfully treated with RR4-7 antibody to prevent C6VL tumor growth were rechallenged with the same tumor cells without further antibody treatment (Table III) . All of these mice showed complete resistance to further tumor challenge.
Discussion
In this article we use an experimental murine model to show that a rat mAb of the IgG2b isotype specific for an epitope determined by the TCR V06 gene is effective in preventing growth in vivo of a syngeneic T cell tumor expressing a V06 TCR. This antibody appears to be effective in inhibiting tumor growth without any significant compromise to the immune status of the treated host despite the fact that it also eliminates normal T cells of the V06+ subset that comprise nearly 10°Io of the peripheral T lymphocyte pool . Two lines of evidence support the conclusion that the effectiveness of anti V06 in inhibiting tumor growth is dependent on expression of a target molecule on tumor cells that is some epitope of the V06 gene product of the TCR. Mice treated with mAb specific for a different V(3 epitope, V08, do not show inhibition of V06 tumor growth, and mice treated with antiV06 show no growth inhibition of EL4, a different syngeneic T cell tumor.
How treatment with antiVO antibodies inhibits growth of V(3+ tumor cells in vivo is not clear, but two general possibilities can be considered . First, like MHC/antigen, mAbs specific for T cell receptors cause activation and lymphokine production of T cell hybridomas, and subsequent inhibition of growth both in vivo and in vitro (18, 19) . However, we could find no evidence of the capacity of C6VL tumor cells to respond in any way to stimulation with RR4-7 in vitro. Thus we consider it unlikely that elimination of V06+ tumor cells with anti V06 antibody requires their activation in vivo. Secondary, anti V(3 antibodies might participate in some cellular mechanism involving binding to Fc receptors of effector cells to cause inhibition of tumor growth . In favor of this possibility is the fact that antibodies of the rat IgG2b subclass have been found to be the most effective in eliminating target cells in vivo (20) . In addition, in not yet complete studies, we have found that anti-V06 together with murine spleen cells bearing Fc receptor inhibit the growth of C6VL in vitro, and that treatment of mice in vivo with F(ab')2 fragment of anti V06 mAb is not as effective as treatment with the whole molecule .
The findings that anti-V06-treated mice that survived initial tumor challenge are resistant to further challenge without additional treatment with antibody is particularly striking . In these experiments, the number of normal peripheral V06+ T cells had returned to normal, thus it seems unlikely that residual levels of anti V06 antibody from the first treatment can account for subsequent tumor resistance . Active immunization of mice with irradiated syngeneic tumor cells also causes resistance to subsequent challenge. Thus, our provisional interpretation of the effect of these antibodies is that they retard tumor growth by some cell-mediated, Fc-dependent mechanism to a degree sufficient to permit the opportunity for host immune antitumor responses that would otherwise be overwhelmed by rapid tumor cell growth .
The findings that antitumor treatment with antiV(3 antibody does not compromise the immune response capacity to other test antigens despite the fact that a significant portion of the peripheral T cell pool is also eliminated do not rule out the possibility that lack of T cells bearing one particular V gene segment may cause a deficit in the response to certain antigens. However, these findings are comparable to the prior studies, in that nearly one-third of Va chains are genetically deleted in certain strains of mice, causing a significant deficit in the expressed repertoire of TCR without jeopardizing their immune response potential .
While the mechanisms ofantiV(3 antibody protection against T cell tumor growth clearly need to be investigated further, the important point to emphasize here is that an epitope expressed on a TCR V gene product of normal cells can be used as a target molecule for mAb therapy of a T cell neoplasm . Since the number of genes encoding known TCR V/3 segment is only 21 in mouse and 35 in man (13) , it seems a reasonable approach to establish panels of mAb specific for each V/3 gene segment for use both diagnostically and therapeutically in the treatment of T cell tumor expressing clonally distributed TCR (21) .
Summary
To test whether antibodies directed to TCR affect T cell tumor growth in vivo, mice were inoculated intravenously with C6VL tumor cells expressing V06 TCR and then treated intraperitoneally with mAb specific for Va6 TCR . Administration ofantiV06 antibody prolonged survival ofmice bearing V06-expressing tumor cells and it led to the induction of host immunity to the tumor cells in surviving animals . This treatment eliminated not only tumor cells bearing Va6 TCR but also normal host T cells expressing V06 T cell receptors . However, the lack of V06-expressing T cells in such treated mice did not result in generalized immune disfunction . These data demonstrate the utility of antiTCR V segment antibody in the treatment of T cell tumors. Most importantly, since the number of V genes for the T cell antigen receptor is limited, both in man and in mouse, it should be possible to establish a panel of mAbs directed to each V gene product and use such antibodies in the treatment of T cell neoplasms. 
